Articles From: ANSYS And Reaction Design Announce Signing Of Definitive Merger Agreement to Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men


2013/12/4
Addition of chemistry simulation software leader bolsters ANSYS' product portfolio PITTSBURGH and SAN DIEGO , Dec.
Sign-up for ANSYS And Reaction Design Announce Signing Of Definitive Merger Agreement investment picks
2014/2/10
PITTSBURGH, Feb.
Sign-up for ANSYS Announces Senior Management Transition in Apache Design Business investment picks
2014/1/13
Stunning multiphysics simulation images showcase potential solutions to complex engineering challenges PITTSBURGH , Jan.
Sign-up for ANSYS Announces Winners Of 2014 Hall Of Fame Competition investment picks
PITTSBURGH , Oct.
Sign-up for ANSYS Breaks into Top Hundred on Software 500 List investment picks
New agreement helps Ferrari motor past competition, leading to more victory laps PITTSBURGH , Sept.
Sign-up for ANSYS Brings Advanced Simulation To GT Racing With Extended Ferrari Partnership investment picks
2013/11/18
PITTSBURGH, Pa., Nov.
Sign-up for ANSYS CEO to Present at the NASDAQ OMX 30th Investor Program in London, UK investment picks
2014/1/3
PITTSBURGH and SAN DIEGO, Jan.
Sign-up for ANSYS Closes Acquisition of Reaction Design investment picks
2014/1/29
New technology delivers end-to-end signal integrity analysis in single user interface PITTSBURGH and SANTA CLARA, Calif.
Sign-up for ANSYS Debuts New Electromagnetic Simulation Suite For Printed Circuit Board Design investment picks
2013/12/3
ANSYS 15.0 Improves Best-in-Class Software for Structures, Fluids and Electromagnetics Simulation PITTSBURGH , Dec.
Sign-up for ANSYS Releases New Version Of Flagship Products investment picks
2014/4/11
PITTSBURGH, April 11, 2014 (GLOBE NEWSWIRE) -- ANSYS, Inc. (Nasdaq:ANSS) announced today that the Company expects to release its first quarter 2014 earnings on Thursday, May 1, 2014.
Sign-up for ANSYS to Release First Quarter 2014 Earnings on May 1, 2014 investment picks
2014/1/27
PITTSBURGH, Jan.
Sign-up for ANSYS to Release Fourth Quarter and YTD 2013 Earnings on February 27, 2014 investment picks
PITTSBURGH, Pa., Oct.
Sign-up for ANSYS to Release Third Quarter 2013 Earnings on November 7, 2013 investment picks
PathFinder™-Dynamic From ANSYS Subsidiary Apache Design Wins Integrated Circuit Design Tool Category PITTSBURGH , Feb.
Sign-up for ANSYS Wins DesignCon Vision Award For Third Year Running investment picks
2014/2/25
PITTSBURGH, Feb.
Sign-up for ANSYS, Inc. Announces Annual Meeting of Stockholders and Sets Record Date investment picks
2013/12/12
Company's fourth quarter EPS will be favorably impacted by approximately $11 million, or $0.11 - $0.12 per share PITTSBURGH , Dec.
Sign-up for ANSYS, Inc. Receives Formal Notice From The Joint Committee On Taxation That Finalizes FY 2009 And 2010 Tax Return Refund Claims investment picks
2014/2/24
PITTSBURGH, Feb.
Sign-up for ANSYS, Inc. Replenishes Authorized Share Repurchase Program to Three Million Shares investment picks
2014/2/27
Management Provides Initial Q1 2014 Outlook and Increases FY 2014 Outlook t o Reflect the Inclusion of Reaction Design Highlights Fourth quarter GAAP revenue of $236.0 million and non-GAAP revenue of $236.7 million Fiscal year 2013 GAAP revenue of $861.3 million and non-GAAP revenue of $865.9 million Fourth quarter GAAP diluted EPS of $0.80* and non-GAAP diluted EPS of $0.96* Fiscal year 2013 GAAP diluted EPS of $2.58* and non-GAAP diluted EPS of $3.27* Operating cash flows of $85.0 million for the fourth quarter and $333.0 million for fiscal year 2013 Fourth quarter and fiscal year 2013 GAAP operating profit margins of 39.1% and 37.4%, respectively, and non-GAAP operating profit margins of 49.0% and 48.9%, respectively Repurchase of 506,000 shares in the fourth quarter and 1.5 million shares in FY 2013 *The Company's GAAP and non-GAAP results include approximately $11.0 million of incremental tax
Sign-up for ANSYS, Inc. Reports Final Results for 2013: Record Revenue and Earnings for the Fourth Quarter and Fiscal Year 2013 investment picks
2013/8/1
Quarterly Highlights: GAAP revenue of $214.9 million and non-GAAP revenue of $216.2 million GAAP diluted earnings per share of $0.59 and non-GAAP diluted earnings per share of $0.77 Operating cash flows of $87.1 million, a 16% increase over the 2012 comparable quarter GAAP operating profit margin of 36.5% and non-GAAP operating profit margin of 48.4% Repurchased 988,000 shares at an average price of $74.35 PITTSBURGH, Aug.
Sign-up for ANSYS, Inc. Reports Record Q2 2013 Results investment picks
Highlights GAAP revenue of $212.7 million and non-GAAP revenue of $213.4 million GAAP diluted earnings per share of $0.66* and non-GAAP diluted earnings per share of $0.83* Operating cash flows of $65.4 million GAAP operating profit margin of 38.4% and non-GAAP operating profit margin of 49.8% *The Company's GAAP results include approximately $5.6 million, or $0.06 per share, related to incremental tax benefits beyond the Company's forecasted effective tax rate range of 30.5% - 31.5%. These incremental benefits relate mainly to legal entity restructuring, cash repatriation activities and adjustments to reserves for uncertain tax positions.
Sign-up for ANSYS, Inc. Reports Record Third Quarter Results Highlighting Strong Margins and EPS investment picks
2014/3/10
PITTSBURGH, March 10, 2014 (GLOBE NEWSWIRE) -- ANSYS, Inc. (Nasdaq:ANSS) will be webcasting the ANSYS 2014 Investor Day being held at the Pittsburgh Fairmont Hotel on March 12, 2014.
Sign-up for ANSYS, Inc. to Webcast 2014 Investor Day investment picks
2014/4/2
New capabilities deliver end-to-end workflow for radio frequency, microwave, antenna and signal integrity design PITTSBURGH , April 2, 2014 /PRNewswire/ -- ANSYS ® (NASDAQ: ANSS) HFSS™ users can reduce design time and cost while optimizing complete electronic system performance, thanks to linear circuit simulation included with the latest version of this software.
Sign-up for ANSYS® HFSS™ Now Includes Circuit Simulation For More Efficient Electronic System Design and Validation investment picks
2013/9/26
PITTSBURGH , Sept.
Sign-up for ANSYS/Apache and TSMC Collaborate on 16-nanometer FinFET Reference Flow and 3D-IC Reference Flow investment picks
2013/9/3
SCOTTSDALE, AZ , Sept.
Sign-up for Antaga International Corporation Appoints New President and CEO investment picks
2013/9/9
Antaga International to assume new name and symbol as management initiates nationwide re-launch of popular drink brand.
Sign-up for Antaga International Corporation Initiates Name Change in Preparation for Product Launch investment picks
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from a pivotal clinical trial of OTREXUP™ (methotrexate) for subcutaneous injection were selected for live, oral presentation during a clinical treatment strategies sub-session of the 2013 American College of Rheumatology (ACR) Annual Meeting, in San Diego.
Sign-up for Antares Announces Podium Presentation of Pivotal OTREXUP™ (methotrexate) Data at American College of Rheumatology Annual Meeting investment picks
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patent 8,579,865. This new patent is related to a previously issued U.S. patent 8,480,631, and includes additional claims that describe injection devices for the subcutaneous delivery of methotrexate.
Sign-up for Antares Pharma Announces Additional U.S. Patent Protection for OTREXUP™ investment picks
2014/1/15
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of OTREXUP ™ , the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Sign-up for Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children investment picks
2013/9/16
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patients have been dosed in a clinical study evaluating testosterone enanthate administered weekly by subcutaneous injection at doses of 50 mg and 100 mg via the VIBEX™ QuickShot™ auto injector device in testosterone deficient adult males.
Sign-up for Antares Pharma Announces First Patients Dosed in VIBEX™ QS T Study Evaluating Testosterone Deficient Males investment picks
2014/3/10
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma’s launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.
Sign-up for Antares Pharma Announces LEO Pharma’s Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis investment picks
2014/2/20
Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous injection at doses of 50 mg and 100 mg using the VIBEX QuickShot auto injector in testosterone deficient adult males.
Sign-up for Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ANSYS And Reaction Design Announce Signing Of Definitive Merger Agreement to Antares Pharma Announces Positive Results from the VIBEX QuickShot Pharmacokinetic Study in Testosterone Deficient Men
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity